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Altered Na Currents in Atrial Fibrillation
Effects of Ranolazine on Arrhythmias
and Contractility in Human Atrial Myocardium
Samuel Sossalla, MD,* Birte Kallmeyer, MS,* Stefan Wagner, MD,* Marek Mazur, MS,*
Ulrike Maurer, MS,* Karl Toischer, MD,* Jan D. Schmitto, MD,† Ralf Seipelt, MD,†
Friedrich A. Schöndube, MD,† Gerd Hasenfuss, MD,* Luiz Belardinelli, MD,‡ Lars S. Maier, MD*
Göttingen, Germany; and Palo Alto, California
Objectives We investigated changes in Na currents (INa) in permanent (or chronic) atrial fibrillation (AF) and the effects of
INa inhibition using ranolazine (Ran) on arrhythmias and contractility in human atrial myocardium.
Background Electrical remodeling during AF is typically associated with alterations in Ca2 and K currents. It remains un-
clear whether INa is also altered.
Methods Right atrial appendages from patients with AF (n  23) and in sinus rhythm (SR) (n  79) were studied.
Results Patch-clamp experiments in isolated atrial myocytes showed significantly reduced peak INa density (16%) in AF
compared with SR, which was accompanied by a 26% lower expression of Nav1.5 (p  0.05). In contrast, late
INa was significantly increased in myocytes from AF atria by 26%. Ran (10 mol/l) decreased late INa by
60% (p  0.05) in myocytes from patients with AF but only by 18% (p  0.05) in myocytes from SR atria.
Proarrhythmic activity was elicited in atrial trabeculae exposed to high [Ca2]o or isoprenaline, which was signifi-
cantly reversed by Ran (by 83% and 100%, respectively). Increasing pacing rates from 0.5 to 3.0 Hz led to an
increase in diastolic tension that could be significantly decreased by Ran in atria from SR and AF patients.
Conclusions Na channels may contribute to arrhythmias and contractile remodeling in AF. Inhibition of INa with Ran had
antiarrhythmic effects and improved diastolic function. Thus, inhibition of late INa may be a promising new treat-
ment option for patients with atrial rhythm disturbances and diastolic dysfunction. (J Am Coll Cardiol 2010;55:
2330–42) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.055a
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Atrial fibrillation (AF) is the most common arrhythmia and
s associated with substantial morbidity and mortality (1,2).
ajor determinants of electrical remodeling in AF include:
) reduced action potential duration (APD); 2) decreased
-type Ca2 current amplitude; and 3) altered K currents
3,4). Whether electrical remodeling in permanent (or
hronic) AF also affects Na channels is unclear. Evidence
omes from 2 nonclinical studies showing reduced peak
a current (INa) densities in dog models of experimentally
nduced AF (5,6).
There is increasing recognition of the importance of a
mall persistent component of INa (late INa). Although the
rom the Departments of *Cardiology and Pneumology and †Thoracic and Cardio-
ascular Surgery, Georg-August-University Göttingen, Göttingen, Germany; and
Gilead Sciences, Inc., Palo Alto, California. This work was funded by the DFG
hrough a Heisenberg grant (MA1982/4-1), the Klinische Forschergruppe (MA1982/
-2), and CV Therapeutics. Drs. Maier and Hasenfuss have a collaboration/grant
ith CV Therapeutics. Dr. Belardinelli is an employee of CV Therapeutics (now
ilead Sciences).t
Manuscript received July 28, 2009; revised manuscript received November 16,
009, accepted December 7, 2009.mplitude of this current is only 1% of the peak INa, due
o its persistent nature during the action potential (AP), it
an contribute to the amount of Na that enters the cell.
he late INa integral seems to be significantly larger than the
eak INa integral under pathological conditions (7). There is
vidence of an increased late INa in ventricular myocytes of
atients with heart failure and myocardial ischemia (8,9),
hich may contribute to the increased [Na]i observed
10–12). However, the role of late INa in atrial myocytes of
F patients is not known. Thus, our first objective was to
etermine whether AF is associated with altered Na
hannel expression as well as changes in peak and late INa
ompared with sinus rhythm (SR).
See page 2343
Ventricular proarrhythmia and negative inotropy are
mportant limitations to the current drug therapies used in
F (13). Thus, the development of agents that preferen-ially modulate the function of atrial rather than ventricular
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anolazine (Ran) is an antianginal agent that preferentially
nhibits late over peak INa in ventricular myocytes (14–16).
large clinical trial (MERLIN–TIMI 36 [Metabolic Ef-
ciency With Ranolazine for Less Ischemia in Non–ST-
levation Acute Coronary Syndromes–Thrombolysis In
yocardial Infarction 36]) revealed that Ran significantly
educes the incidence of supraventricular arrhythmias and
ew episodes of AF in patients with non–ST-segment
levation acute coronary syndrome (17). In canine perfused
ight atrial preparations, Burashnikov et al. (18) demon-
trated differences in the inactivation characteristics of atrial
ersus ventricular Na channels, and an atrial selective
ction of Ran to cause a use-dependent block of Na
hannels and suppression of AF. Hence, our second objec-
ive was to determine the effects of Ran on peak and late INa
f atrial myocytes from patients with AF and SR.
Last, the third objective was to determine the effects of
an on contractile function as well as possible antiarrhyth-
ic properties in human atrial trabeculae.
ethods
issue. Right atrial appendages were obtained from pa-
ients undergoing heart surgery who were in SR or perma-
ent AF (Table 1). All procedures were in compliance with
he ethical committee of Georg-August-University
öttingen.
ell isolation. Pieces of atrial myocardium were trans-
orted to the laboratory in cardioplegic solution (mmol/l:
aCl 110, KCl 16, MgCl2 16, NaHCO3 16, CaCl2 1.2,
lucose 11) immediately after excision. They were rinsed,
ut into small pieces, and incubated (36°C) in a Ca2-free
olution containing 1.4 mg/ml collagenase (Worthington
ype 2, 290 U/mg), 30 g/ml proteinase (Sigma type
XIV, 9 U/mg), and (mmol/l): NaCl 88, sucrose 88, KCl
.4, NaHCO3 4, NaH2PO4 0.3, MgCl2 1.1, 4-(2-
ydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
0, taurine 20, glucose 10, sodium pyruvate 5 (pH 7.4).
fter 45 min, the supernatant was discarded. The tissue was
igested again in a collagenase solution until myocytes
ppeared. Solutions containing cells were centrifuged at 60
pm (3 min). In the following steps, the same solution was
sed and aliquots were incubated (10 to 15 min). This
rocedure was repeated 4 to 5 times. Cells were stored for
h in medium containing (mmol/l): taurine 10, glutamic
cid 70, KCl 25, KH2PO4 10, dextrose 22, ethylene glycol
etraacetic acid 0.5 (pH 7.4, KOH). Only elongated cells
ith cross striations and without granulation were used.
atch-clamp experiments. Whole-cell voltage-clamp was
sed to measure INa (12). Microelectrodes (2 to 3 M) were
lled with (mmol/l): 40 CsCl, 80 Cs glutamate, 10 NaCl,
.92 MgCl2, 5 magnesium adenosine triphosphate, 0.3
ithium guanosine triphosphate, 10 HEPES, 0.03 niflu-
ic acid, 0.02 nifedipine, 0.004 strophanthidin, 5 (1,2-
is(o-aminophenoxy)ethane-N,N,N=,N=-tetraacetic acid) oMtetracesium salt), 1 5,5=-dibromo
1,2-bis(o-aminophenoxy) ethane-
,N,N=,N=-tetraacetic acid)
tetrapotassium salt), 1.49
aCl2 (free [Ca
2]i  100
mol/l; pH 7.2, CsOH). The
ath solution contained (mmol/l):
30 NaCl, 10 tetraethylammo-
ium chloride, 4 CsCl, 1 MgCl2,
0 glucose, 10 HEPES or 10
aCl, 130 tetramethylammonium
hloride, 4 CsCl, 1 MgCl2, 10
lucose, 10 HEPES (pH 7.4,
aOH). Note that the high
Na] solution was used for late
Na measurements (12,14). Myo-
ytes were placed in a recording
hamber mounted on the stage of
microscope. Fast capacitance was
ompensated in cell-attached con-
guration. Liquid junction poten-
ials (3 to 6 mV) were corrected. Membrane capacitance and
eries resistance were compensated after rupture; access resis-
ance was 10 M. Recordings were started 5 min after
upture. Signals were filtered with 2.9- and 10-kHz Bessel
lters and recorded with an EPC10 amplifier (HEKA Elek-
ronik, Lambrecht/Pfalz, Germany). Myocytes were held at
atient CharacteristicsTable 1 Patient Characteristics
SR AF
n 79 23
Age, yrs 68 1* 73 1
Male 50 (63.3) 13 (60.8)
Surgery
CABG 39 (49.4) 8 (34.8)
AVR 13 (16.5) 7 (30.4)
MVR 1 (1.3) 3 (13.0)
CABG  AVR 12 (15.3) 3 (13.0)
CABG  MVR 2 (2.5) 2 (8.7)
HTX 3 (3.8) 0 (0.0)
HOCM 9 (11.4) 0 (0.0)
Drug treatment
Ca2-channel blocker 14 (17.7) 6 (26.1)
Beta-blocker 61 (77.2) 18 (78.3)
ACE inhibitor 46 (58.2) 14 (60.9)
Amiodarone 4 (5.1) 2 (8.7)
Diuretic 39 (49.4) 14 (60.9)
Catecholamines 2 (2.5) 0 (0.0)
LV function
EF 45% 53 (67.1) 11 (55.0)
EF 35%–45% 18 (22.8) 7 (35.0)
EF 35% 8 (10.1) 2 (10.0)
LA diameter (mm) 42.6 1* 51.3 1
alues are n, mean  SEM, or n (%). *p  0.05 SR versus AF.
ACE  angiotensin-converting enzyme; AF  atrial fibrillation; AVR  aortic valve replacement;
ABG  coronary artery bypass graft surgery; EF  ejection fraction; HOCM  hypertrophic
Abbreviations
and Acronyms
AF  atrial fibrillation
ANOVA  analysis of
variance
AP  action potential
APD  action potential
duration
HEPES  4-(2-hydroxyethyl)-
1-piperazineethanesulfonic
acid
INa  Na
 current
Iso  isoprenaline
ITi  transient inward
current
PAC  premature atrial
contraction
Ran  ranolazine
SR  sinus rhythmbstructive cardiomyopathy; HTX  heart transplantation
VR  mitral valve replacement; SR  sinus rhythm.; LA  left atrial; LV  left ventricular;
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30 mV. To measure peak INa, myocytes were held at 80
V followed by a depolarizing step to 30 or 10 mV.
urrent-voltage (I-V) relationships were generated using a
olding potential of120 mV followed by steps from80 to
30 mV (0.5 Hz). For the measurement of late INa, pulses
ere preceded by a 5-ms pre-pulse to 50 mV to optimize
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Figure 1 Altered Na Currents and Channel Expression in AF V
(A) Original peak Na current (INa) tracings. (B) Mean peak INa in atrial fibrillation
hearts; p  0.05). (C) Western blots for Nav1.5. (D) Mean data for Nav1.5 in AF
in AF versus SR (n  13 cells from 9 hearts vs. 30 cells from 16 hearts, p  0.0
n  10), Nav1.6 (AF, n  6 vs. SR, n  5). *p  0.05 versus SR. A/F  ampere
measure analysis of variance.oltage control. Measured currents were normalized to the
embrane capacitance. Late INa was measured and integrated
rom 50 to 250 ms of the beginning of the depolarizing pulse
room temperature).
estern blots. Atrial tissue was homogenized in Tris
uffer containing (mmol/l): 20 Tris-HCl, 200 NaCl, 20
aF, 1 Na3VO4, 1 dithiothreipol, 1% Triton X-100 (pH
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gnostics, Grenzach-Wyhlen, Germany). Protein concen-
ration was determined by bicinchoninic acid assay (Pierce
iotechnology, Rockford, Illinois). Denatured cell lysates and
issue homogenates (30 min, 37°C, 2% -mercaptoethanol)
ere subjected to Western blotting (7.5% sodium
odecylsulfate-polyacrylamide gel) using cardiac-specific anti-
av1.5 (1:500), neuronal anti-Nav1.1, anti-Nav1.6 (1:400,
lomone Labs, Jerusalem, Israel), anti-glyceraldehyde-3-
hosphate dehydrogenase (1:20,000, Biotrend Chemikalien,
öln, Germany) as primary, and a horseradish peroxidase-
onjugated donkey anti-rabbit and sheep anti-mouse immu-
oglobulin G (1:10,000, Amersham Biosciences, Freiburg,
ermany) as secondary antibody. Chemiluminescent detec-
ion was performed with SuperSignal West Pico Substrate
Pierce Biotechnology).
reparation of right atrial trabeculae. Thin right atrial
rabeculae were microdissected (19) in a cardioprotective
olution (mmol/l): Na 152, K 3.6, Cl 135, HCO3
 25,
g2 0.6, H2PO4
 1.3, SO4
2 0.6, Ca2 2.5, glucose 11.2,
,3-butanedione monoxime oxygenated (95% O2, 5%
O2). Trabeculae were mounted in an organ chamber and
onnected to a force transducer. Trabeculae were superfused
ith solution (mmol/l: NaCl2 116, KCl 5, NaH2PO4 2,
gCl2 1.2, Na2SO4 1.2, NaHCO3 20, CaCl2 0.25, glucose
0) that was oxygenated (95% O2, 5% CO2, 37°C) and
timulated at 1 Hz (voltage 25% above threshold, pulse
idth of 5 ms). Ca2 was added stepwise every 2 min until
he final concentration of 1.25 mmol/l was reached. After an
quilibration period (45 min), the trabeculae were gradually
tretched until maximum steady-state twitch force was
chieved.
rug solutions and experimental protocol. Ran ([]N-
2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)-
ropyl)-1-piperazine acetamide dihydrochloride]) was freshly
issolved in 10% HCl solution. In trabeculae experiments,
he Ran concentration used was 10 mol/l because it is
ithin the range of therapeutic plasma levels (10 mol/l)
nd inhibitory concentration of 50% values for inhibition of
ate INa (6 to 15 mol/l), which does not significantly
nhibit ICa, INa/Ca, or IKs (15). A force-frequency relation-
hip was obtained by increasing stimulation rates from 0.5
o 3.0 and back to 1 Hz. To measure sarcoplasmic reticulum
haracteristics, post-rest behavior was assessed by measuring
orce after rest intervals of 10 and 30 s at 1 Hz (20).
remature atrial contractions (PACs) were induced using
igh Ca2 (5 mmol/l) or isoprenaline (Iso) (30 nmol/l). To
nduce Na overload and diastolic dysfunction, we used
.25 mol/l ouabain (21).
ata analysis and statistics. Force values were normalized
o cross-sectional areas of each trabeculae (width 	 thick-
ess 	 /4) and expressed as mN/mm2. All data are
xpressed as mean  SEM. Student t test, 2-way repeated-
easures analysis of variance (ANOVA) with Holm-Sidak nests, 2-way ANOVA, or the Fisher exact test was used to
est for significance where appropriate and as indicated in
he figures (p  0.05).
esults
Na in AF versus SR. Peak and late INa were measured in
trial myocytes. The magnitude of peak INa over a broad
ange of stimulation frequencies was significantly smaller
etween both groups (2-way repeated-measures ANOVA) of
trial myocytes from patients with AF versus SR (Figs. 1A and
B). Mean peak INa at 1 Hz was71.5 3.7 for AF versus
84.9  3.1 A/F for SR (p  0.05, Holm-Sidak). This
16% smaller peak INa was accompanied by a reduced
xpression of the cardiac Na-channel isoform Nav1.5 by
26% in AF (74  6%) versus SR (100  8%) (p  0.05)
Figs. 1C and 1D).
In marked contrast, late INa (Figs. 1E and 1F) was
ignificantly greater (26% at 2 Hz, p  0.05, Holm-
idak) between both groups of myocytes from AF versus SR
atients (2-way repeated-measures ANOVA) with a similar
ifference over the wide range of frequencies studied
Fig. 1F) (p  0.05). Membrane capacitances of myocytes
n both groups were not different for each dataset used
Table 2). Because late INa may also be due to altered
xpression of other Na-channel isoforms, 2 neuronal
a-channel isoforms were studied. An increase in Nav1.1
by 59  22%, p  0.05) but no change in Nav1.6 protein
xpression (7  9%) in AF versus SR was observed (Figs.
G and 1H). In summary, divergent regulation of peak
ersus late INa was found in AF versus SR patients.
nhibition of INa. Paired experiments were performed with
an to determine its effect on peak and late INa. Ran
ignificantly inhibited peak INa in atrial myocytes from SR
atients (Figs. 2A and 2B). To perform experiments at more
hysiological holding potentials, myocytes were held at80
V followed by a depolarization step to 30 mV (high
Na]o) or10 mV (low [Na
]o); at high [Na
]o peak, INa
as reduced by 15.0  3.6% at 1 Hz and 22.2  6.3% at 3
z (p  0.05, n  5 cells from 3 hearts each; data not
hown) showing no difference to our observations at more
embrane CapacitancesTable 2 Membrane Capacitances
Figure Membrane Capacitance (pF)
1B AF: 114 5 vs. SR: 105 5
1F AF: 105 12 vs. SR: 88 5
2B Vehicle/Ran 10 mol/l: 90 7 vs. Ran 20 mol/l: 95 19
2C Vehicle: 78 5 vs. Ran: 73 10
2D Vehicle: 105 13 vs. Ran: 86 6
2E Vehicle: 114 11 vs. Ran: 124 11
3B Vehicle: 89 9 vs. Ran: 97 10
3C Vehicle: 114 11 vs. Ran: 117 12
o statistical significance could be obtained.
Abbreviations as in Tables 1 and 2.egative holding potential (Figs. 2A and 2B). Experiments
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eak INa by Ran (1 Hz: 24  2 for Ran vs. 34  8 A/F
or vehicle; 3 Hz: 21  2 for Ran vs. 36  8
mpere/farrad (A/F) for vehicle, p  0.05; data not
hown). In contrast, in myocytes from patients with AF,
an reduced peak INa density only slightly, without
tatistical significance (Fig. 2C). In contrast, I-V rela-
ionships (Fig. 2D) in SR myocytes illustrate a typical
-V relationship in which Ran again reduced peak INa
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rabeculae (p  0.05), which corresponds to an 83%
uccess rate for terminating PACs (Fig. 4B). In contrast,
n vehicle-treated trabeculae, no PAC could be termi-
ated (0 out of 6).
The incidence of Iso-induced PACs in vehicle- and
an-treated trabeculae was 38% versus 14% (Fig. 5A). Ran
as effective in converting PACs to a regular rhythm (7 of
, p  0.05) (Fig. 5B). Original tracings show that a PAC
as abolished by Ran (Figs. 5C and 5D). In trabeculae from
atients with AF (Figs. 5E and 5F), Ran was also effective
n preventing (Fig. 5E) and terminating PACs (Fig. 5F).
hese data show that Ran also has antiarrhythmic proper-
ies in AF trabeculae.
an reduces atrial twitch amplitude concentration
ependently. Increasing concentrations of Ran (6, 10, 15
mol/l) reduced twitch amplitude (p 0.05) in SR and AF
rabeculae (Fig. 6). This effect was reversible on washout of
he drug (Fig. 6B) (mean twitch amplitude in vehicle- and
an-treated trabeculae was 3.1  0.5 mN/mm2 vs. 3.7 
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Figure 3 Ranolazine Inhibits Late INa
(A) Original recordings in an AF myocyte. (B) Mean late INa in SR myocytes
(Ran vs. vehicle, n  9 cells from 8 hearts vs. 30 cells from 16 hearts, p 
0.05). (C) Mean late INa in AF myocytes (Ran vs. vehicle, n  10 cells from 5
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0.05 versus baseline. Abbreviations as in Figure 1..6 mN/mm2). Because Ran improves diastolic function in euman ventricular failing myocardium (16), we investigated
trial contractile function during increasing stimulation
requencies.
ffects of Ran on contractile function during increasing
requencies. At all stimulation rates, a slight negative
notropic effect of Ran was observed (Fig. 7A). Ran
educes diastolic tension in SR trabeculae (p  0.05)
Fig. 7B). Relaxation parameters were also assessed, but
an only caused a small acceleration of relaxation time at
and 3 Hz (Table 3).
In line with this, sarcoplasmic reticulum function was not
ltered in atrial trabeculae treated with Ran as assessed by
ost-rest twitches (Figs. 7C and 7D).
Interestingly, we found that AF trabeculae (Fig. 7D)
howed a slight positive force-frequency relationship. How-
ver, AF trabeculae generated twitches with lower ampli-
ude compared with SR. The beneficial effect of Ran on
iastolic tension was similar in atrial trabeculae from pa-
ients with AF (Fig. 7E) compared with SR (Fig. 7B).
ffects of Ca2 and Iso on diastolic performance. The
mall negative inotropic effect of Ran was still present at
igh [Ca2] (Fig. 8A). Ran slightly reduced the increases in
iastolic tension at higher [Ca2] (Fig. 8B). In Iso-treated
rabeculae, force amplitude was significantly reduced by Ran
t low Iso concentrations (Fig. 8C). Although force ampli-
ude did not differ between Ran- and vehicle-treated tra-
eculae in the presence of high Iso concentrations, diastolic
ension was significantly reduced by Ran (Fig. 8D). To
nduce Ca2 overload and severe diastolic dysfunction by
ifferent means, ouabain was added to the bath solution
Fig. 8E). Ran significantly delayed the time to contracture
p 0.05) (Fig. 8F). Taken together, the negative inotropic
ffect of Ran was associated with beneficial effects on
iastolic performance under different “stress” conditions
i.e., increasing stimulation frequencies, Iso, or ouabain).
iscussion
he results show that permanent AF is associated with
ltered expression and function of Na channels. Although
av1.5 expression and peak INa density were significantly
educed in AF compared with SR, late INa was significantly
reater as well as Nav1.1 expression. Ran reduced peak and
ate INa in SR, but it preferentially blocked late over peak
Na in AF. Ran reduced Ca
2- and Iso-induced PACs and
aused a concentration-dependent and reversible negative
notropic effect associated with an improved diastolic ten-
ion at: 1) higher stimulation frequencies; 2) high [Ca2]o;
nd 3) in the presence of Iso. Moreover, ouabain-induced
iastolic contracture was attenuated by Ran.
ltered Na-channel expression and function in AF. AF
s associated with changes in atrial function and structure
21–24) and electrical remodeling (3,4). Na channels play
crucial role in cardiac excitation-contraction coupling by
nitiating the AP (25,26). The present study provides
vidence that expression of Nav1.5 and peak INa density is
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s plausible that the decreased peak INa may be partly due to
he down-regulation of Nav1.5 expression. Similar findings
ere reported by Yue et al. (27) showing a reduction of
a-channel -subunit protein and mRNA expression in
trial myocardium of dogs with AF. This observation is in
eeping with their previous findings of significantly less INa
ensity in the same model (5), which has been confirmed in
nother AF dog model (6). Bosch et al. (28) reported that
either current density nor the INa voltage dependence was
ltered in human AF, although there was a trend toward a
10% reduction in INa density. However, our 16% reduc-
ion in peak INa density is consistent with the decreased
a channel protein expression of 26% and is in line with
he results in dog AF models (5,27). It should be noted that
e also recognize the difficulty in accurately measuring peak
Na but have taken all precautions to correctly assess peak
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elease channel (ryanodine receptor [RyR]), augmenting
pontaneous Ca2-release events. By removing Ca2 from
he cytosol, the Na/Ca2 exchanger generates a transient
nward current (ITi), giving rise to delayed afterdepolariza-
ions and possibly to the PACs observed. A recent study in
uinea-pig atrial myocytes demonstrated that increased late
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Figure 6 Concentration-Dependent
Effect of Ran on Force Amplitude
(A) Original recordings in SR trabeculae. (B) Mean data showing a negative
inotropic effect (vehicle vs. Ran n  12 cells from 7 hearts vs. 12 cells from
10 hearts, p  0.05) reversible on washout (p  0.2 vehicle vs. Ran). (C)
Mean data for AF trabeculae (vehicle vs. Ran n  5 cells from 3 hearts vs. 6
cells from 3 hearts, p  0.05). *p  0.05 versus vehicle. Abbreviations as in
Figures 1 and 2.18) reported on the atrial versus ventricular selectivity to lnhibit peak INa but without quantifying the effect of Ran on
ate INa in atrial myocytes. Because Ran is known to act as
n inactivated state blocker (31), a more depolarized resting
embrane potential (18), a less steep repolarization phase in
tria, and shorter diastolic intervals at rapid rates may
ccount for the effect of Ran on peak INa (42). Consistent
ith this, our results show that at increased stimulation
requencies, Ran caused a greater inhibition of peak INa.
owever, other studies also suggested that Ran prefer-
ntially binds to open versus inactivated Na channels
43,44).
The preferential inhibition of Ran on peak INa in SR
ersus AF myocytes may be attributed to a rightward shift of
he steady-state inactivation curve of peak INa in AF (28).
his may decrease the percentage of inactivated Na
hannels and increase the fraction of resting Na channels,
educing binding and promoting unbinding of Ran. Impor-
antly, the smaller inhibition of peak INa by Ran in AF is
esirable because the drug would be expected to cause less
lowing of conduction velocity.
Which patients might clinically benefit from Ran? Inhi-
ition of late INa would be expected to further shorten APD
n AF. However, there are reports of APD prolongation
eading to polymorphic atrial tachycardia that degenerates
nto AF (45). Similarly, APD prolongation has been re-
orted in atria of patients with heart failure (46), dilated
tria (47), atrial tachyarrhythmias having long QT syn-
romes 1 and 2 (48), and an Na channel mutation
esponsible for long QT syndrome 3 and familial AF (49).
n this latter study, flecainide shortened QT interval and
erminated AF.
What may be the effect of Ran in most other AF patients
ith shortened APD? Of note, Burashnikov et al. (18)
howed that Ran does not shorten APD but rather even
lightly prolongs APD in dog atrial myocytes. This may
ave been due to the fact that Ran also inhibits IKr (14).
ost importantly, these authors could suppress experimen-
ally induced AF. Therefore, we believe that there may be
lso beneficial effects of Ran independent of APD (e.g., by
ecreasing Na and Ca2 overload).
an terminates Iso- and Ca2-induced PACs. Ran was
ound to prevent and suppress Ca2- and Iso-induced
ACs. This effect may be explained by 2 mechanisms: first,
he inhibition of Na channels, IKr, and, to a lesser
xtent, late ICa (14); and second, Ran inhibits late INa,
hich should reduce intracellular [Na] and consequently
ytosolic [Ca2] via the Na/Ca2 exchanger. This would
esult in reduced sarcoplasmic reticulum Ca2 load and
educed RyR open probability, rendering spontaneous
arcoplasmic reticulum Ca2 release and ITI less likely.
oth Iso and increased [Ca2]o have the opposite effect;
hey increase sarcoplasmic reticulum Ca2 load and
pontaneous Ca2 release and thereby the likelihood of
TI. The antiarrhythmic effects of Ran observed are
onsistent with abolished early afterdepolarizations, de-
ayed afterdepolarizations, and triggered activity induced
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aintain SR in patients with resistant AF (50). The
nhibitory effects of Ran on late INa and IKr are likely to
lay an important role in the antiarrhythmic properties in
he atrium.
ffects of Ran on atrial contractility. Ran reduced atrial
ontractility. Several antiarrhythmic agents depress ventric-
lar contractility. This is an undesirable effect, especially in
atients with reduced left ventricular function. In contrast,
an exerts no negative inotropic effect on the left ventricular
Figure 7 Effect of Ran on Contractile Behavior During Increasin
(A) Mean force amplitude for SR (n  24 cells from 20 hearts vs. 23 cells from 2
malized steady-state (SS) contraction. (D) Mean force amplitude of AF trabeculae
post-rest twitches (n  7 cells from 5 hearts vs. 9 cells from 6 hearts). Abbreviati
Twitch Parameters of Trabeculae From PatientsTable 3 Twitch Parameters of Trabeculae Fr
0.5
TTP Ran, ms 143 7
TTP vehicle, ms 142 8
RT50% Ran, ms 69 4
RT50% vehicle, ms 67 4
RT90% Ran, ms 175 13
RT90% vehicle, ms 168 15Ran  ranolazine; RT50%  time to 50% relaxation; RT90%  time to 90% reyocardium (16,51). Regardless, the difference between
entricular and atrial myocardial responsiveness to Ran
ight be explained by the distinct electrophysiological
roperties of both tissues.
Ran reduced the increase in diastolic tension associated with
ast stimulation rates in SR and AF trabeculae and also during
tress conditions. This suggests that Na overload and hence
a2 overload may contribute to diastolic dysfunction in atrial
rabeculae, even if others found preserved atrial relaxation and
nimpaired diastolic function in AF (52). Because many
imulation Rates
rts). (B) Average diastolic force. (C) Mean values of post-rest twitches (PR) nor-
1 cells from 8 hearts each). (E) Average diastolic force. (F) Mean values of
in Figures 1 and 2.
nus Rhythmatients in Sinus Rhythm
Frequency (Hz)
1 2 3
 10 140 8 135 9
 12 148 14 131 5
 10 67 3 63 3
 5 71 6 71 6
 14 153 11 143 8
 11 162 13 148 7g St
1 hea
(n  1
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ependent signaling pathways, this observation may be of interest.
he reduction of load due to the decrease in diastolic tension may
low or even reverse atrial remodeling. Decreased diastolic tension
ould also reduce sarcoplasmic reticulum Ca2 load and the
ikelihood of ITI due to changes in AP morphology (53).
onclusions
ecent studies revealed a potential role for Na channels in
he pathogenesis of AF (6,7). The results of the present
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hannel dysregulation that leads to changes in AP morphol-
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uppresses known proarrhythmogenic mechanisms in vitro.
his points to a potentially new therapeutic benefit of this
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May 25, 2010:2330–42 Role of Na Current Inhibition in Atrial MyocardiumOne major limitation is that only right atrial appendages
ere used instead of more relevant left atrial tissue. It is
enerally accepted that right atrial appendages do not
ignificantly contribute to the initiation or perpetuation
f AF. Therefore, one should not extrapolate our findings
or AF in general. It is unclear whether the cellular
roarrhythmic mechanism described here is applicable to
he clinical situation whereby a left atrial re-entry mech-
nism is a key mechanism underlying AF. The fact that
an improves diastolic tension and also suppresses ar-
hythmogenic events in AF and SR trabeculae questions
hether late INa inhibition solely contributes to these
eneficial effects. Nevertheless, these novel findings
hould trigger further studies.
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